Bilateral toxoplasmosis retinitis associated with ruxolitinib

New England Journal of Medicine

Volumn 369, Issue 7, 2013, Pages 681-683

  Goldberg, Roger A ^a   Reichel, Elias ^a   Oshry, Lauren J ^b  

^a NEW ENGLAND EYE CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CLINDAMYCIN; COTRIMOXAZOLE; CYTOKINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; JANUS KINASE; RUXOLITINIB; STAT PROTEIN;

AGED; CASE REPORT; ENDEMIC DISEASE; FLUORESCENCE ANGIOGRAPHY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MALE; MYELOFIBROSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETINA MACULA LUTEA; RETINITIS; SPLENOMEGALY; TOXOPLASMA GONDII; TOXOPLASMOSIS; URINE CULTURE; VISION; VISUAL ACUITY; VITRECTOMY;

EID: 84881416684     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1302895     Document Type: Letter

References (5)

1. Harrison C, Kiladjian J-J, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-98.
2. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807.
3. Martina MN, Cervera C, Esforzado N, et al. Toxoplasma gondii primary infection in renal transplant recipients: two case reports and literature review. Transpl Int 2011;24(1):e6-e12.
4. Butcher BA, Fox BA, Rommereim LM, et al. Toxoplasma gondii rhoptry kinase ROP16 activates STAT3 and STAT6 resulting in cytokine inhibition and arginase-1-dependent growth control. PLoS Pathog 2011;7(9):e1002236.
5. Labalette P, Delhaes L, Margaron F, Fortier B, Rouland JF. Ocular toxoplasmosis after the fifth decade. Am J Ophthalmol 2002;133:506-15. (Pubitemid 34258059)